Cook Zenith Alpha 内移植物:减少分支移植物闭塞的方案
这项在两家大学血管外科中心开展的非申办方资助的回顾性研究,纳入2016至2019年547例标准主髂动脉腔内修复术(EVAR),评估遵循预防分支相关并发症的标准化方案后分支移植物闭塞(LGO)发生率。平均随访44±23个月,5年免于LGO为97±3%,三组间无差异(p=.080);Zenith Alpha组中,髂外动脉远端锚定和大尺寸主体(ZIMB 32-36)与LGO独立相关。
要点
- 遵循标准化预防方案后,5年免于LGO为97±3%,三种移植物间无差异(p=.080)。
- Zenith Alpha组髂外动脉远端锚定与LGO独立相关(HR 18,95%CI 3-130,p=.004)。
- Zenith Alpha组大尺寸主体(ZIMB 32-36)与LGO独立相关(HR 12,95%CI 1.2-130,p=.030)。
核心结论
- 遵循预防分支相关并发症的方案,Zenith Alpha内移植物5年LGO率低,与其他内移植物相似。
- Cook Zenith Alpha内移植物的特定危险因素为髂外动脉远端锚定和使用大尺寸主体(ZIMB 32-36)。
研究设计与样本
- 非申办方资助的回顾性研究,在两家大学血管外科中心开展,2016至2019年采用同一预防分支并发症方案。
- 共纳入547例标准主髂动脉EVAR:Cook Zenith Alpha 233例(42.6%),Gore Excluder 196例(35.8%),Medtronic Endurant 118例(21.6%)。
- 方案包括:导航前对狭窄>50%的髂总或髂外动脉行血管成形术;分支近端密封区与血流分叉同一水平且最小重叠;半顺应性球囊对吻扩张;对残余扭曲、折角或狭窄行分支支架置入;EVAR后对残余狭窄或夹层行髂总及髂外动脉辅助支架置入。
- 随访方式为出院时、6个月及此后每年临床访视和多普勒超声。
主要发现
- 平均随访44±23个月,5年免于LGO为97±3%,组间无差异(Cook Zenith Alpha 97±2%、Medtronic Endurant 95±3%、Gore Excluder 100%;p=.080)。
- Zenith Alpha组术中辅助髂动脉血管成形术、髂动脉支架置入、髂分支支架置入分别占8%、3.4%、9.7%。
- LGO潜在危险因素分析显示,髂外动脉远端锚定与LGO独立相关(HR 18,95%CI 3-130,p=.004)。
- 大尺寸主体(ZIMB 32-36)与LGO独立相关(HR 12,95%CI 1.2-130,p=.030)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Numerous articles have reported an increased incidence of limb graft occlusion (LGO) with the Cook Zenith Alpha endograft compared with other endografts in endovascular aortic aneurysm repair (EVAR). The present study aimed to assess the rate of LGO after EVAR in particular with the Cook Zenith Alpha device when adhering to a standardised protocol designed to prevent limb related complications. METHODS: This was a non-sponsored retrospective study performed in two university vascular surgery centres employing the same protocol for limb complication prevention during EVAR from 2016 to 2019. The protocol encompassed: (1) angioplasty of any common or external iliac artery with > 50% stenosis before endograft navigation; (2) proximal sealing zone of limbs at the same level of the flow divider with minimum overlap, which is more restrictive than the Cook Zenith Alpha instructions for use; (3) semi-compliant kissing ballooning of limbs; (4) limb stenting for any residual tortuosity, kinking, or stenosis; and (5) adjunctive common and external iliac stenting for residual stenosis or dissection after EVAR. Patients enrolled in this study were treated with standard aortobi-iliac EVAR. Follow up was performed by clinical visit and duplex ultrasonography at discharge, six months, and yearly thereafter. The primary endpoint was to evaluate the LGO rate with different EVAR devices (Cook Zenith Alpha, Gore C3, and Medtronic Endurant) and to determine potential risk factors for LGO associated with the Zenith Alpha. RESULTS: In the study period, 547 EVARs were considered: 233 (42.6%) Cook Zenith Alpha, 196 (35.8%) Gore Excluder, and 118 (21.6%) Medtronic Endurant. The mean follow up was 44 ± 23 months, and the five year freedom from LGO was 97 ± 3%, without differences between groups (97 ± 2%, 95 ± 3%, and 100% with Cook Zenith Alpha, Medtronic Endurant, and Gore Excluder, respectively; p = .080). In the Zenith Alpha group, intra-operative adjunctive iliac artery angioplasty, iliac artery stenting, or iliac limb stenting was performed in 8%, 3.4%, and 9.7% of cases, respectively. Analysis of potential risk factors for LGO identified external iliac artery distal landing and large main bodies (ZIMB 32 - 36) to be independently associated with LGO during follow up (hazard ratio [HR] 18, 95% confidence interval [CI] 3 - 130, p = .004; and HR 12, 95% CI 1.2 - 130, p = .030, respectively). CONCLUSION: The present experience with a protocol for limb complication prevention allows achievement of a low rate of LGO at five years with Zenith Alpha endografts similar to other endografts. Specific risk factors for the Cook Zenith Alpha endograft are external iliac artery distal landing and the use of a large main body (ZIMB 32 - 36).
引用
- Pini R, Bianchini Massoni C, Faggioli G, et al. Cook Zenith Alpha Endograft: A Protocol to Minimise Limb Graft Occlusion. Eur J Vasc Endovasc Surg. 2024. PMID: 38936689. doi:10.1016/j.ejvs.2024.06.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。